| Not Yet Recruiting | Perennial Malaria Chemoprevention in the Malaria Vaccine Era NCT07322068 | Stanford University | Phase 4 |
| Recruiting | Safety, Tolerability and Efficacy Against Controlled Human Malaria Infection of PfSPZ-LARC2 Vaccine in Malaria NCT06862453 | Sanaria Inc. | Phase 1 |
| Active Not Recruiting | A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 With Matrix-M in Combination With R21/Matri NCT07183371 | University of Oxford | Phase 2 |
| Recruiting | A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 Combined With R21/Matrix-M (a "Multi-stage" NCT06958198 | University of Oxford | Phase 1 |
| Active Not Recruiting | Safety and Immunogenicity of SUM-101 Malaria Vaccine in Children and Infants Living in Burkina Faso NCT06618885 | European Vaccine Initiative | Phase 1 |
| Not Yet Recruiting | Experimental Malaria Infection of Healthy Malaria-Naive Adults by Mosquito Bite With the Genetically Modified NCT06881732 | University of Melbourne | Phase 1 |
| Recruiting | Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of LAI MMV055 Alone and in NCT07011511 | Medicines for Malaria Venture | Phase 1 |
| Recruiting | An Observational Study to Assess Effectiveness and Safety of The R21/Matrix-M Malaria Vaccine NCT07009847 | Serum Institute of India Pvt. Ltd. | — |
| Recruiting | Serological Testing and Treatment for Plasmodium Vivax Malaria: a Trial in Ethiopia and Madagascar NCT06923592 | London School of Hygiene and Tropical Medicine | Phase 3 |
| Active Not Recruiting | IGHID 12334 - After the Flood: Optimal Strategies to Prevent Malaria Epidemics Caused by Severe Flooding NCT06870344 | University of North Carolina, Chapel Hill | N/A |
| Completed | Age De-escalation Safety Trial of PfSPZ-LARC2 Vaccine in Burkina Faso NCT06652737 | Sanaria Inc. | Phase 1 |
| Not Yet Recruiting | Durability of Protection After Single Immunisation With GA2 Sporozoites (CoGA-Rechallenge) NCT06293339 | Leiden University Medical Center | Phase 1 |
| Active Not Recruiting | Preventing Malaria in School Children to Protect the Whole Community in Rural Blantyre District, Malawi NCT06083688 | Liverpool School of Tropical Medicine | Phase 4 |
| Active Not Recruiting | MDA and Targeted Control Against Plasmodium Carriage in the Sahel NCT07281443 | Institut de Recherche pour le Developpement | N/A |
| Completed | Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of MMV371 LAI in Healthy P NCT06558643 | Medicines for Malaria Venture | Phase 1 |
| Completed | Safety, Pharmacokinetics, and Plasmodium Falciparum Transmission-reducing Activity of Monoclonal Antibody TB31 NCT06413108 | Radboud University Medical Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Host Immune Dynamics Following Seasonal Malaria Chemoprevention in African Children NCT06524336 | Malaria Consortium | — |
| Not Yet Recruiting | The Impact RTS,S/AS01 Vaccine in School Aged Children RTS,S/AS01 Malaria Vaccine in School Aged Children NCT06424002 | Kamuzu University of Health Sciences | Phase 4 |
| Completed | Clinical Practices for Treating Severe Malaria Caused by P. Falciparum NCT07027722 | Centre Hospitalier de Saint-Denis | — |
| Unknown | Seasonal Malaria Chemoprevention Rapid Assessment Study Mozambique NCT06337253 | Malaria Consortium | Phase 4 |
| Active Not Recruiting | A Phase 1 Study to Assess an Escalating Dose, Multi-prime Vaccination Schedule of R21/Matrix-M™ NCT06320535 | University of Oxford | Phase 1 |
| Not Yet Recruiting | Addressing Asymptomatic Plasmodium Reservoirs to Accelerate Malaria Elimination and Eradication in Rwanda. NCT05801198 | King Faisal Hospital Rwanda | Phase 2 |
| Completed | Private Medicine Retailer-based Trial of Malaria Tests and Conditional Treatment Subsidies Among Patients With NCT06928207 | Clinton Health Access Initiative Inc. | Phase 4 |
| Recruiting | A Study to Investigate the Safety of GSK4024484 in Healthy Adult Participants NCT06171113 | GlaxoSmithKline | Phase 1 |
| Recruiting | Improving Neonatal Health Through Rapid Malaria Testing in Early Pregnancy With High-Sensitivity Diagnostics NCT05757167 | Duke University | Phase 4 |
| Recruiting | Assessing the Feasibility of Combining Dihydroartemisinin Piperaquine and Primaquine for Malaria Mass Drug Adm NCT07389057 | Noguchi Memorial Institute for Medical Research | N/A |
| Active Not Recruiting | A Study to Assess the Safety and Effectiveness of Two Experimental Malaria Vaccines NCT05978037 | University of Oxford | Phase 1 / Phase 2 |
| Completed | Phase 1b MMV367 PK/PD and Safety in Healthy Adult Volunteers Experimentally Infected With Blood Stage P. Falci NCT05979207 | Medicines for Malaria Venture | Phase 1 |
| Completed | CHILD (Child Health and Infection With Low Density) Malaria NCT05567016 | University of California, San Francisco | N/A |
| Completed | Understanding and Maximizing the Community Impact of Antimalarial Treatment (INDIE-SMC) NCT05878366 | London School of Hygiene and Tropical Medicine | N/A |
| Active Not Recruiting | A Study to Compare Two Dosing Regimens for a New Malaria Vaccine NCT06141057 | University of Oxford | Phase 1 |
| Recruiting | A Study to Test Experimental Blood Stage Malaria Vaccine in Burkina Faso. NCT05790889 | University of Oxford | Phase 1 / Phase 2 |
| Unknown | MSP3-CRM-Vac4All/ Alhydrogel® Vaccine NCT05776017 | Vac4All | Phase 1 / Phase 2 |
| Active Not Recruiting | Pharmacokinetics of Antimalarials in Breastfeeding Ugandan Mother-infant Pairs NCT05676645 | University of Liverpool | — |
| Completed | Comparing Chemoprevention Drugs for School-based Malaria Control NCT05980156 | University of Maryland, Baltimore | Phase 4 |
| Unknown | Coadministration of GA2 Sporozoites With Adjuvants NCT05468606 | Leiden University Medical Center | EARLY_Phase 1 |
| Active Not Recruiting | A Phase Ia Clinical Trial to Assess the Safety and Immunogenicity of the Blood-stage Malaria Candidate Vaccine NCT05385471 | University of Oxford | EARLY_Phase 1 |
| Completed | Safety and Immunogenicity of the Malaria Vaccine, R21/MatrixM, in Healthy Thai Adults NCT05252845 | University of Oxford | Phase 2 |
| Terminated | A Phase 1 Trial of PfSPZ Vaccine in Healthy Adults to Determine Safety, Tolerability and Efficacy Against Hete NCT05604521 | Sanaria Inc. | Phase 1 |
| Completed | Gametocytocidal and Transmission-blocking Efficacy of ASAQ and ALAQ With or Without PQ in Mali NCT05550909 | London School of Hygiene and Tropical Medicine | Phase 2 |
| Completed | Performance of an Ultrasensible Malaria Rapid Diagnostic Test Among Pregnant Women in Burkina Faso NCT06572644 | Centre MURAZ/Institut National de Santé Publique | — |
| Terminated | A Study to Determine if New Types of Malaria Vaccines Are Safe, Effective and Lead to Immunity in Kenyan Adult NCT03947190 | University of Oxford | Phase 2 |
| Suspended | Controlled Human Malaria Infection Transmission Model - Phase A NCT04280692 | University of Oxford | Phase 1 / Phase 2 |
| Completed | First-in-Human Study to Assess the Safety, Tolerability and Pharmacokinetics of MMV367 NCT05507970 | Medicines for Malaria Venture | Phase 1 |
| Unknown | Association of Diabetes and Metabolic Syndrome With Severe Malaria in Cameroon NCT05685875 | Karolinska Institutet | — |
| Unknown | Plasmodium Vivax Among Duffy Negative Population in Cameroon. NCT05058885 | University of Dschang | — |
| Completed | Pyronaridine in Healthy Adult Participants Infected With Blood Stage Malaria NCT05287893 | Medicines for Malaria Venture | Phase 1 |
| Completed | PfSPZ Vaccine Trial in Malian Children NCT04940130 | Sanaria Inc. | Phase 2 |
| Completed | Comparing Chemoprevention Approaches for School-based Malaria Control NCT05244954 | University of Maryland, Baltimore | Phase 4 |
| Unknown | Effect of Paracetamol on Kidney Function in Severe Malaria NCT04251351 | University of British Columbia | Phase 3 |
| Unknown | MSP3-CRM-Vac4All/ Alhydrogel® Malaria Vaccine NCT05197751 | Vac4All | Phase 1 |
| Completed | Short Course Radical Cure of P. Vivax Malaria in Nepal NCT04079621 | Menzies School of Health Research | Phase 4 |
| Completed | Study of the Transmission-Blocking Vaccine Pfs230D1-EPA/Matrix-M Against Malaria in Adults in Mali NCT05135273 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | Gametocytocidal and Transmission-blocking Efficacy of PQ in Combination With AL and TQ in Combination With SPA NCT05081089 | London School of Hygiene and Tropical Medicine | Phase 2 |
| Completed | Plasmodium Falciparum Genomic Intelligence in Mozambique NCT05306067 | Centro de Investigacao em Saude de Manhica | — |
| Completed | Association Between Drug Levels, Malaria, and Antimalarial Resistance in the Setting of Seasonal Malaria Chemo NCT04969185 | University of California, San Francisco | — |
| Unknown | Evaluation of Insecticide-treated Eave Nets and Window Screens for Malaria Control in Tanzania. NCT05125133 | Ifakara Health Institute | N/A |
| Completed | Mass Drug Administration of Dihydroartemisinin-piperaquine + Single Low-dose Primaquine to Accelerate Toward E NCT04864444 | University of California, San Francisco | N/A |
| Terminated | Safety, Immunogenicity and ex Vivo Efficacy of Pfs25-IMX313/Matrix-M in Healthy Volunteers in Bagamoyo, Tanzan NCT04271306 | University of Oxford | Phase 1 |
| Completed | Safety and Efficacy of R0.6C Vaccine NCT04862416 | Radboud University Medical Center | Phase 1 |
| Unknown | Adjunctive Ivermectin Mass Drug Administration for Malaria Control NCT04844905 | London School of Hygiene and Tropical Medicine | Phase 3 |
| Completed | Proactive Community Case Management for Malaria in Zambia NCT04839900 | PATH | N/A |
| Completed | Efficacy of SJ733 in Adults With Uncomplicated Plasmodium Falciparum or Vivax Malaria NCT04709692 | R. Kiplin Guy | Phase 2 |
| Completed | Health Itinerary of Young Children With Suspected Bloodstream Infection in Kisantu General Referral Hospital, NCT04289688 | Institute of Tropical Medicine, Belgium | — |
| Completed | Clinical Decision Support in Non-typhoidal Salmonella Bloodstream Infections in Children NCT04473768 | Institute of Tropical Medicine, Belgium | — |
| Completed | Safety and Immunogenicity of RH5.1/Matrix-M in Adults and Infants Living in Tanzania NCT04318002 | University of Oxford | Phase 1 |
| Unknown | Attractive Targeted Sugar Bait Phase III Trial in Zambia NCT04800055 | PATH | N/A |
| Completed | Single Low Dose Tafenoquine to Reduce P. Falciparum Transmission in Mali (NECTAR2) NCT04609098 | London School of Hygiene and Tropical Medicine | Phase 2 |
| Unknown | Vectron T500 (Broflanilide 50WP) for IRS in Tanzania Tanzania NCT05150808 | London School of Hygiene and Tropical Medicine | Phase 3 |
| Completed | Health Systems Implementation and Molecular Surveillance of Multiple First-Line Treatments for Uncomplicated M NCT07362498 | Strathmore University | — |
| Completed | Seasonal Malaria Vaccination (RTS,S/AS01) and Seasonal Malaria Chemoprevention (SP/AQ) Extension Study NCT04319380 | London School of Hygiene and Tropical Medicine | Phase 3 |
| Completed | Study in Blood Stage Malaria Infection After DVI of Cryopreserved P. Falciparum (NF54 Strain) Sporozoites NCT04310085 | Medicines for Malaria Venture | Phase 1 |
| Completed | Safety, Tolerability, and Pharmacokinetics and Pharmacodynamics of TB31F NCT04238689 | Radboud University Medical Center | Phase 1 |
| Terminated | VAC077: Safety and Immunogenicity of the Pfs25-IMX313/Matrix-M Vaccine NCT04130282 | University of Oxford | Phase 1 |
| Completed | Pyronaridine-artesunate With Low Dose Primaquine for Preventing P. Falciparum Transmission NCT04049916 | London School of Hygiene and Tropical Medicine | Phase 2 / Phase 3 |
| Unknown | Seasonal Malaria Chemoprevention With Dihydroartemisin Piperaquin vs. Sulfadoxine-pyrimethamin+Amodiaquin NCT04149106 | University Clinical Research Center, Mali | Phase 3 |
| Completed | Effectiveness and Safety of Artesunate-Amodiaquine and Artemether-Lumefantrine for the Treatment of Malaria in NCT04565184 | University of Yaounde 1 | Phase 4 |
| Completed | Safety, Immunogenicity and Efficacy of R21 Matrix-M in 5-17 Month Old Children in Nanoro, Burkina Faso NCT03896724 | University of Oxford | Phase 1 / Phase 2 |
| Completed | A Study to Determine if a New Malaria Vaccine is Safe and Induces Immunity Among Kenyan Adults, Young Children NCT03580824 | University of Oxford | Phase 1 / Phase 2 |
| Terminated | Safety and Efficacy of NF135 CPS Immunization NCT03813108 | Radboud University Medical Center | N/A |
| Completed | Effectiveness and Safety of Intermittent Preventive Treatment for Malaria Using Either Dihydroartemisinin-pipe NCT03640403 | National Institute for Medical Research, Tanzania | Phase 3 |
| Completed | To Assess the Safety, Immunogenicity and Efficacy of VLPM01 in Healthy, Malaria-Naïve Volunteers NCT03867331 | VLP Therapeutics | Phase 1 |
| Completed | Evaluate the Infectivity Equivalence of Current and New Lots of Plasmodium Falciparum Strain NF54 NCT03882528 | U.S. Army Medical Research and Development Command | Phase 1 |
| Completed | Malaria Vaccine Pilot Evaluation NCT03806465 | Rafiq OKINE | — |
| Completed | Combination Momordica Charantia Extract and Primaquine Againts Plasmodium Falciparum Uncomplicated and Plasmod NCT06036030 | Syamsudin Abdillah,Ph.D, Pharm D | Phase 2 |
| Unknown | Pyramax in Asymptomatic Carriers of P. Falciparum Monoinfections NCT03814616 | Shin Poong Pharmaceutical Co. Ltd. | Phase 2 |
| Completed | Controlled Human Malaria Infection Model for Evaluation of Transmission-blocking Interventions - Study 2 NCT03454048 | Radboud University Medical Center | N/A |
| Completed | Safety and Immunogenicity of ChAd63 RH5 and MVA RH5 in Adults, Young Children and Infants Living in Tanzania NCT03435874 | University of Oxford | Phase 1 |
| Completed | Study to Compare the Triple ACT AL+AQ With the ACT AL in Cambodia and Vietnam NCT03355664 | University of Oxford | Phase 3 |
| Completed | Study to Evaluate Safety, Immunogenicity and Efficacy of PfSPZ Vaccine in HIV Negative and HIV Positive Tanzan NCT03420053 | Sanaria Inc. | Phase 1 |
| Completed | Enhancing Preventive Therapy of Malaria In Children With Sickle Cell Anemia in East Africa (EPiTOMISE) NCT03178643 | Duke University | Phase 4 |
| Withdrawn | Chemoprotective Activity of MMV390048 in PfSPZ Challenge Model NCT03195387 | Medicines for Malaria Venture | Phase 1 |
| Unknown | Evaluation of the Performance of a hsRDT Versus cRDT in Reactive Case Detection of Malaria Infections NCT03511443 | University Research Co, LLC | N/A |
| Completed | "Prolonging the Therapeutic Life Span of Artemisinin-based Combination Therapies (ACT) in Bagamoyo District, T NCT03241901 | Muhimbili University of Health and Allied Sciences | Phase 4 |
| Completed | Cohort Event Monitoring Study of Pyramax® NCT03201770 | Shin Poong Pharmaceutical Co. Ltd. | Phase 4 |
| Unknown | Non-specific Effects of Vaccination on Mortality and Morbidity NCT03176719 | Radboud University Medical Center | — |
| Completed | Safety and Protective Efficacy of Pb(PfCS@UIS4) NCT03138096 | Radboud University Medical Center | Phase 1 / Phase 2 |
| Completed | Seasonal Malaria Vaccination (RTS,S/AS01) and Seasonal Malaria Chemoprevention (SP/AQ) NCT03143218 | London School of Hygiene and Tropical Medicine | Phase 3 |
| Completed | TES of Artemether-lumefantrine for Pf in the Philippines in 2017-2018 NCT05958810 | Research Institute for Tropical Medicine, Philippines | — |
| Completed | Methylene Blue Against Falciparum Malaria in Burkina Faso NCT02851108 | Heidelberg University | Phase 2 |
| Completed | Therapeutic Efficacy Study of AL and DP in Western Kenya NCT05060198 | Kenya Medical Research Institute | N/A |
| Completed | A Microdose Study in Healthy Subjects to Describe Intravenous Pharmacokinetics of GSK3191607 NCT02737007 | GlaxoSmithKline | Phase 1 |
| Completed | A Study by the Tracking Resistance to Artemisinin Collaboration (TRAC) NCT02453308 | University of Oxford | Phase 2 / Phase 3 |
| Completed | Malawi International Center of Excellence in Malaria Research School-based Cohort NCT04858087 | University of Maryland, Baltimore | — |
| Completed | Efficacy and Safety of Pyronaridine-artesunate for the Treatment in Uncomplicated Falciparum Malaria NCT02389439 | University of Oxford | Phase 2 |
| Completed | TES of Artemether-lumefantrine for Pf in the Philippines in 2015 NCT05958693 | Research Institute for Tropical Medicine, Philippines | — |
| Completed | Artemisinin-based Combination Therapy for Treatment of Plasmodium Falciparum Malaria in North Sumatera, Indone NCT02325180 | London School of Hygiene and Tropical Medicine | Phase 4 |
| Terminated | MMV390048 Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Participants NCT02281344 | Medicines for Malaria Venture | Phase 1 |
| Completed | Safety and Tolerability of Low Dose Primaquine NCT02434952 | Malaria Consortium | Phase 4 |
| Completed | Mass Drug Administration With Dihydroartemisinin + Piperaquine for Reducing Malaria in Southern Zambia NCT02329301 | PATH | N/A |
| Completed | Assessment of Artesunate/Mefloquine in the Peruvian Amazon NCT02084602 | Instituto Nacional de Salud. Peru | Phase 4 |
| Completed | In Vivo Efficacy of Artemether-Lumefantrine and Artesunate-Amodiaquine for Uncomplicated P. Falciparum Malaria NCT02637128 | Centers for Disease Control and Prevention | Phase 4 |
| Completed | Liberia Insecticide Treated Durable Wall Linings Study: Protocol for a Cluster Randomised Trial (DL) NCT02448745 | The Mentor Initiative | N/A |
| Completed | Safety, Tolerability, Pharmacokinetics and Efficacy of ARCO NCT01930331 | Ifakara Health Institute | Phase 4 |
| Completed | Safety and Immunogenicity of Recombinant Pichia Pastoris AMA1-DiCo Candidate Malaria Vaccine With GLA-SE and A NCT02014727 | Institut National de la Santé Et de la Recherche Médicale, France | Phase 1 |
| Completed | A Pharmacokinetic/Pharmacodynamic Study of Eurartesim Dispersible Formulation in Infants With P.Falciparum Mal NCT01992900 | sigma-tau i.f.r. S.p.A. | Phase 2 |
| Unknown | Artemether/ Lumefantrine: A Study of the Effect of Local Food on Pharmacokinetics and Population Pharmacokinet NCT01944189 | Makerere University | Phase 4 |
| Completed | Evaluation of Community-based Mass Screening and Treatment for Malaria in Western Kenya NCT02987270 | Simon Kariuki | Phase 3 |
| Withdrawn | Immunization With Plasmodium Falciparum Sporozoites Under Chloroquine or Chloroquine/Azithromycin Prophylaxis NCT01783340 | Radboud University Medical Center | Phase 1 / Phase 2 |
| Completed | Malaria Transmission Studies in Mali NCT01829737 | National Institute of Allergy and Infectious Diseases (NIAID) | — |
| Completed | Re-exposure of Human Volunteers to a Heterologous Strain of P. Falciparum Sporozoites NCT01660854 | Radboud University Medical Center | N/A |
| Terminated | Sevuparin/DF02 as an Adjunctive Therapy in Subjects Affected With Uncomplicated Falciparum Malaria NCT01442168 | Modus Therapeutics AB | Phase 1 / Phase 2 |
| Completed | Time to Become Negative of Three Rapid Diagnostic Tests for Malaria NCT01325974 | Epicentre | — |
| Completed | Efficacy of Artemether-lumefantrine, Artesunate-amodiaquine and Dihydroartemisinin-piperaquine for the Treatme NCT01326754 | Centers for Disease Control and Prevention | N/A |
| Unknown | Impact of Insecticide Resistance on Vector Control NCT01713517 | London School of Hygiene and Tropical Medicine | Phase 4 |
| Completed | Efficacy, Tolerability, PK of OZ439 in Adults With Acute, Uncomplicated P.Falciparum or Vivax Malaria Mono-inf NCT01213966 | Medicines for Malaria Venture | Phase 2 |
| Completed | Pilot Study to Estimate the Burden and Distribution of Plasmodium Falciparum Malaria in Kalifabougou, Mali in NCT01160562 | National Institute of Allergy and Infectious Diseases (NIAID) | — |
| Completed | Iron Absorption and Utilization in Adolescents Infected With Malaria Parasites, Hookworms or Schistosoma NCT01163877 | Swiss Federal Institute of Technology | N/A |
| Completed | Food Interaction Study on the Pharmacokinetics of Eurartesim™ (DHA and PQP)in Healthy Male Adult Volunteers NCT01222962 | sigma-tau i.f.r. S.p.A. | Phase 1 |
| Completed | Safety Study on the Effect of Eurartesim™ on QT/QTc Interval Compared to Riamet in Healthy Volunteers NCT01103830 | sigma-tau i.f.r. S.p.A. | Phase 1 |
| Completed | A Pharmacokinetic (PK) Trial in Healthy Asian and Caucasian Volunteers Investigating the PK Profile of Eurarte NCT01222949 | sigma-tau i.f.r. S.p.A. | Phase 1 |
| Completed | Interactions Between Artemether-lumefantrine and Antiretrovirals in HIV-patients With Uncomplicated Malaria in NCT00885287 | University of Copenhagen | Phase 4 |
| Completed | A Study to Investigate the Safety, Tolerability and Pharmacokinetics of OZ439 in Healthy Male and Female Subje NCT00928083 | Medicines for Malaria Venture | Phase 1 |
| Completed | Study of Iron Absorption and Utilization in Asymptomatic Malaria NCT01108939 | Swiss Federal Institute of Technology | EARLY_Phase 1 |
| Completed | Azithromycin Plus Chloroquine Versus Artemether-Lumefantrine For The Treatment Of Uncomplicated P. Falciparum NCT00677833 | Pfizer | Phase 2 / Phase 3 |
| Completed | Efficacy Study of Amodiaquine-Artesunate and Artemether-Lumefantrine for the Treatment of Uncomplicated Malari NCT01567423 | Epicentre | N/A |
| Completed | Mass-Drug Administration to Reduce Malaria Transmission NCT00509015 | Radboud University Medical Center | N/A |
| Completed | Randomised Efficacy Study of Two Artemether-Lumefantrine Oral Formulations for the Treatment of Uncomplicated NCT00529867 | Dafra Pharma | Phase 4 |
| Completed | Chloroquine and Coartem for Treatment of Symptomatic Children With Plasmodium Falciparum in Guinea Bissau NCT00426439 | Bandim Health Project | Phase 4 |
| Completed | Artemisinin Resistance in Cambodia NCT00479206 | Medical University of Vienna | N/A |
| Completed | Sporozoite Challenge of Polyprotein Vaccinees NCT00375128 | European Vaccine Initiative | Phase 1 / Phase 2 |
| Terminated | Randomized Trial on Effectiveness of ACTs in Ghana NCT00374205 | Bernhard Nocht Institute for Tropical Medicine | Phase 4 |
| Completed | Chlorproguanil-Dapsone-Artesunate Versus COARTEM For Uncomplicated Malaria NCT00344006 | GlaxoSmithKline | Phase 3 |
| Completed | Chlorproguanil-Dapsone-Artesunate (CDA) Versus Chlorproguanil-Dapsone (LAPDAP) For Uncomplicated Malaria NCT00371735 | GlaxoSmithKline | Phase 3 |
| Completed | Safety and Immunogenicity Study of the Malaria Vaccines FP9 PP and MVA PP NCT00374998 | European Vaccine Initiative | Phase 1 |
| Completed | Efficacy of Combined PEV3A Virosomal Vaccine and FP9-MVA ME-TRAP Prime Boost Regimen NCT00408668 | University of Oxford | Phase 1 / Phase 2 |
| Completed | A Randomised Trial of Artekin and Artesunate & Amodiaquine for Uncomplicated Malaria in Timika, Papua, Indones NCT00157885 | Menzies School of Health Research | N/A |
| Completed | Double-blind, Randomized, Controlled Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vacci NCT00223990 | U.S. Army Medical Research and Development Command | Phase 2 |
| Completed | Assessing the Efficacy of Four Drug Combinations as the Next First-line Therapy for Uncomplicated Malaria in M NCT00164710 | Centers for Disease Control and Prevention | Phase 4 |
| Completed | Amodiaquine Plus Artesunate Versus Lapdap Plus Artesunate in the Treatment of Uncomplicated P. Falciparum Mala NCT00164359 | Centers for Disease Control and Prevention | Phase 4 |
| Completed | Efficacy and Effectiveness of Combined Therapy for Uncomplicated Malaria Treatment in Peru NCT00164216 | Centers for Disease Control and Prevention | — |
| Unknown | The Community Effectiveness of IPTi in Southern Tanzania NCT00152204 | Swiss Tropical & Public Health Institute | Phase 3 |
| Completed | Arginine Malaria Trial: Study of Adjunctive Arginine in Falciparum Malaria NCT00147368 | Menzies School of Health Research | Phase 1 / Phase 2 |
| Completed | Study of the Impact of Intermittent Preventive Treatment in Schools on Malaria, Anaemia and Education. NCT00142246 | London School of Hygiene and Tropical Medicine | Phase 3 |
| Terminated | Azithromycin in Combination With Chloroquine Versus Chloroquine in the Eradication of Asymptomatic Plasmodium NCT00082563 | Pfizer | Phase 2 |
| Completed | Azithromycin Plus Chloroquine Versus Atovaquone-Proguanil For The Treatment Of Uncomplicated Plasmodium Falcip NCT00084227 | Pfizer | Phase 2 / Phase 3 |
| Completed | Azithromycin Plus Chloroquine Versus Mefloquine for the Treatment of Uncomplicated Malaria in Africa NCT00082576 | Pfizer | Phase 2 / Phase 3 |
| Terminated | Azithromycin Plus Chloroquine Versus Sulfadoxine-Pyrimethamine Plus Chloroquine For The Treatment Of Uncomplic NCT00084240 | Pfizer | Phase 2 / Phase 3 |
| Completed | Preventing Malaria During Pregnancy in Epidemic-prone Areas. NCT00142207 | London School of Hygiene and Tropical Medicine | Phase 3 |
| Completed | Prevention of Malaria During Pregnancy Using Intermittent Preventive Treatment With Sulfadoxine-Pyrimethamine: NCT00126906 | Centers for Disease Control and Prevention | N/A |
| Completed | The Efficacy of Re-treatment With Sulfadoxine-pyrimethamine in Children NCT00137553 | Bandim Health Project | Phase 4 |
| Completed | Safety and Preliminary Efficacy of the Malaria Vaccine Candidates Falciparum Merozoite Protein-1 (FMP1) and Sm NCT01556945 | U.S. Army Medical Research and Development Command | Phase 1 / Phase 2 |
| Completed | Chloroquine and Amodiaquine for Treatment of Malaria in Children NCT00137514 | Bandim Health Project | Phase 4 |
| Completed | Efficacy, Effect on Gametocytes and Tolerability of the Addition of Artesunate to Amodiaquine in Colombia NCT00378625 | Centro Internacional de Entrenamiento e Investigaciones Médicas | Phase 3 |
| Completed | Therapeutic Efficacy Study of Pyrimethamine/Sulfdoxine (Fansidar®) for the Treatment of Uncomplicated Falcipar NCT00951106 | Walter Reed Army Institute of Research (WRAIR) | N/A |
| Completed | Extended-dose Chloroquine (ECQ) for Resistant Falciparum Malaria Among Afghan Refugees in Pakistan NCT01019408 | London School of Hygiene and Tropical Medicine | Phase 4 |
| Withdrawn | Efficacy of Artesunate-amodiaquine (AS-AQ) in Children With Malaria and Severe Acute Malnutrition, Madaoua, Ni NCT01204411 | Epicentre | Phase 4 |